News >

Cabozantinib Proves Superior to Sunitinib in All Subgroups Examined in CABOSUN

Wayne Kuznar
Published: Monday, Feb 12, 2018

Daniel J. George, MD
Daniel J. George, MD
Cabozantinib (Cabometyx) improved progression-free survival (PFS) compared with sunitinib (Sutent) as initial systemic therapy across subgroups of patients with intermediate- and poor-risk advanced renal cell carcinoma (RCC) enrolled in the randomized phase II CABOSUN trial.1 The advantage to cabozantinib on PFS was particularly strong in patients who were MET-positive.

When asked if cabozantinib should be first-line treatment in a MET-negative intermediate- or poor-risk patients, George replied that subgroup data should be used to generate hypotheses. “I think we have to recognize this as not necessarily a definitive analysis, either by threshold…or by positive or negative status,” he said. “The fact is that we still see a trend in favor of cabozantinib in the MET-negative patients, so I wouldn’t go so far as to say that’s a population that shouldn’t get cabozantinib.”

References

  1. George DJ, Hessel C, Halabi S, et al. Cabozantinib versus sunitinib for previously untreated patients with advanced renal cell carcinoma (RCC) of intermediate or poor risk: subgroup analysis of progression-free survival (PFS) and objective response rate (ORR) in the Alliance A031203 CABOSUN trial. Presented at: 2018 Genitourinary Cancers Symposium; February 8-10, 2018; San Francisco, CA. Abstract 582.
  2. Choueiri TK, Hessel C, Halabi S, et al. Progression-free survival (PFS) by independent review and updated overall survival (OS) results from Alliance A031203 trial (CABOSUN): cabozantinib versus sunitinib as initial targeted therapy doe patients (pts) with metastatic renal cell carcinoma (mRCC). In: Proceedings from the 2017 ESMO Congress; September 8-12, 2017; Madrid, Spain. Abstract LBA38.

... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: 22nd Annual International Congress on Hematologic Malignancies®: Focus on Leukemias, Lymphomas and MyelomaMay 30, 20192.0
Online Medical Crossfire®: 5th Annual Miami Lung Cancer ConferenceMay 30, 20196.5
Publication Bottom Border
Border Publication
x